title: Respiratory syncytial virus bronchiolitis in children.
abstract: Respiratory syncytial virus is a highly infectious virus that commonly causes bronchiolitis and leads to high morbidity and a low, but important, incidence of mortality. Supportive therapy is the foundation of management. Hydration/nutrition and respiratory support are important evidence-based interventions. For children with severe disease, continuous positive airway pressure or mechanical ventilation may be necessary. Ribavirin may be used for treatment of patients with severe disease. Palivizumab provides important ongoing immunoprophylaxis during epidemic months for high-risk infants. Caregiver education and incorporating an explanation of all therapies and anticipatory guidance, including strategies for reducing the risk of infection, are vital.
authors.affiliation: Pediatric Critical Care and Neonatal Nurse Practitioner Programs, School of Nursing, Fagin Hall, 418 Curie Boulevard, University of Pennsylvania, Philadelphia, PA 19104, USA. jtv@nursing.upenn.edu
authors.forename: Judy Trivits
authors.initials: JT
authors.lastname: Verger
authors.forename: Emily Elizabeth
authors.initials: EE
authors.lastname: Verger
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001988:Bronchiolitis / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D045422:Continuous Positive Airway Pressure; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D044623:Nutrition Therapy; D000069455:Palivizumab; D012121:Respiration, Artificial; D018357:Respiratory Syncytial Virus Infections / Q000628:therapy*; D012254:Ribavirin / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D012254:Ribavirin; D000069455:Palivizumab